The primary ciliary dyskinesia (pcd) market size has grown strongly in recent years. It will grow from $0.49 billion in 2025 to $0.53 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to limited awareness about pcd, lack of standardized diagnostic protocols, reliance on conventional antibiotic therapies, minimal availability of specialized clinics, low adoption of airway clearance devices.
The primary ciliary dyskinesia (pcd) market size is expected to see strong growth in the next few years. It will grow to $0.68 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to development of gene therapy and stem cell interventions, increasing investments in diagnostic laboratories, rising prevalence of rare respiratory disorders, adoption of personalized medicine approaches, integration of digital health and remote monitoring solutions. Major trends in the forecast period include increasing adoption of genetic testing for early diagnosis, rising use of advanced imaging techniques for monitoring, expansion of airway clearance therapy devices, growing demand for personalized antibiotic treatments, focus on innovative therapies such as gene and stem cell therapy.
The growing demand for gene therapy is expected to accelerate the expansion of the primary ciliary dyskinesia (PCD) market. Gene therapy involves modifying or replacing faulty genes in a patient's cells to treat or prevent diseases. The demand for gene therapy has surged due to significant progress in genetic research, allowing for more precise treatments that target and correct genetic disorders at the molecular level, improving patient outcomes. In particular, gene therapy is being developed for Primary Ciliary Dyskinesia (PCD) to correct the genetic mutations responsible for defective cilia function in the respiratory system. This therapy aims to introduce healthy genes to restore normal ciliary movement, enhance mucus clearance, and reduce respiratory infections. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, reported that the number of gene therapy programs in Phase II clinical trials reached 260 by the second quarter of 2023, a 5% increase from the first quarter. This growing focus on gene therapy is driving the growth of the primary ciliary dyskinesia market.
Key players in the primary ciliary dyskinesia market are focusing on the development of innovative therapies, such as investigational mRNA-based treatments, to improve symptom management and enhance the quality of life for patients. mRNA-based therapeutics use messenger RNA (mRNA) to instruct cells to produce proteins that may treat or prevent diseases. This cutting-edge approach targets conditions at the molecular level, leading to personalized medicine. For instance, in June 2024, ReCode Therapeutics, Inc., a US-based biotechnology company, launched RCT1100, an investigational inhaled mRNA therapy. The therapy received orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating primary ciliary dyskinesia. RCT1100 aims to restore ciliary function by delivering DNAI1 mRNA directly to airway cells, addressing a critical unmet need for the estimated 45,000 individuals affected by PCD in the U.S., as there are currently no disease-modifying treatments or cures for this condition.
In October 2024, PCD Research, a UK-based charitable organization focused on primary ciliary dyskinesia research, partnered with the Nucleic Acid Therapy Accelerator (NATA) to advance therapies for primary ciliary dyskinesia. The collaboration aims to co-fund a grant dedicated to developing innovative treatments for PCD, a rare genetic disorder that impairs respiratory function. The partnership seeks to support groundbreaking research that will improve treatment options and outcomes for individuals affected by this progressive and debilitating condition. NATA is a UK-based research initiative specializing in nucleic acid therapeutics.
Major companies operating in the primary ciliary dyskinesia (pcd) market are Centogene NV, Revvity Inc, Quest Diagnostics Incorporated, Nationwide Children’s Hospital, Children’s Healthcare of Atlanta, National Jewish Health, Guy's and St Thomas' NHS Foundation Trust, University Hospital Southampton, Vanderbilt University Medical Center, Stanford Medicine, Mayo Foundation for Medical Education and Research, UNC School of Medicine, UAB Health System, University Hospital Münster, DNA Labs India Pvt Ltd, Parion Sciences Inc, ReCode Therapeutics Inc, PCD Foundation, PCD Research Consortium, European PCD Network.
North America was the largest region in the primary ciliary dyskinesia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary ciliary dyskinesia (pcd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the primary ciliary dyskinesia (pcd) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the primary ciliary dyskinesia market by increasing the cost of imported diagnostic equipment, therapeutic devices, and specialized medications. Segments such as genetic testing kits and airway clearance therapy devices are particularly impacted, with regions like North America and Europe facing import duty challenges for specialized medical devices. This has led to higher treatment costs and slowed procurement for small clinics. On the positive side, tariffs encourage local manufacturing of diagnostic tools and therapies, driving innovation and domestic production capabilities.
The primary ciliary dyskinesia (pcd) market research report is one of a series of new reports that provides primary ciliary dyskinesia (pcd) market statistics, including primary ciliary dyskinesia (pcd) industry global market size, regional shares, competitors with a primary ciliary dyskinesia (pcd) market share, detailed primary ciliary dyskinesia (pcd) market segments, market trends and opportunities, and any further data you may need to thrive in the primary ciliary dyskinesia (pcd) industry. This primary ciliary dyskinesia (pcd) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Primary ciliary dyskinesia (PCD) is a rare inherited disorder that affects the normal function and structure of cilia, which are microscopic, hair-like structures found in the airways, ears, and reproductive tract. Understanding and diagnosing PCD is essential for managing symptoms early and improving quality of life through targeted therapies.
The main types of treatment for primary ciliary dyskinesia (PCD) include antibiotics, airway clearance therapies, surgical interventions, and other supportive therapies. Antibiotics help treat respiratory bacterial infections, prevent lung damage, and maintain airway health. PCD is diagnosed through various methods, such as genetic testing, imaging techniques, clinical evaluation, and lung function tests. The treatments are distributed through multiple channels, including direct sales, online pharmacies, third-party distributors, and retail pharmacies. End-users of PCD treatments include hospitals, specialty clinics, diagnostic laboratories, and other healthcare providers.
The primary ciliary dyskinesia market consists of revenues earned by entities by providing services such as pulmonary rehabilitation, home healthcare services, and genetic counselling. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary ciliary dyskinesia market includes sales of immunofluorescence microscopy, transmission electron tomography, and whole-exome sequencing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The primary ciliary dyskinesia (pcd) market size is expected to see strong growth in the next few years. It will grow to $0.68 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to development of gene therapy and stem cell interventions, increasing investments in diagnostic laboratories, rising prevalence of rare respiratory disorders, adoption of personalized medicine approaches, integration of digital health and remote monitoring solutions. Major trends in the forecast period include increasing adoption of genetic testing for early diagnosis, rising use of advanced imaging techniques for monitoring, expansion of airway clearance therapy devices, growing demand for personalized antibiotic treatments, focus on innovative therapies such as gene and stem cell therapy.
The growing demand for gene therapy is expected to accelerate the expansion of the primary ciliary dyskinesia (PCD) market. Gene therapy involves modifying or replacing faulty genes in a patient's cells to treat or prevent diseases. The demand for gene therapy has surged due to significant progress in genetic research, allowing for more precise treatments that target and correct genetic disorders at the molecular level, improving patient outcomes. In particular, gene therapy is being developed for Primary Ciliary Dyskinesia (PCD) to correct the genetic mutations responsible for defective cilia function in the respiratory system. This therapy aims to introduce healthy genes to restore normal ciliary movement, enhance mucus clearance, and reduce respiratory infections. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, reported that the number of gene therapy programs in Phase II clinical trials reached 260 by the second quarter of 2023, a 5% increase from the first quarter. This growing focus on gene therapy is driving the growth of the primary ciliary dyskinesia market.
Key players in the primary ciliary dyskinesia market are focusing on the development of innovative therapies, such as investigational mRNA-based treatments, to improve symptom management and enhance the quality of life for patients. mRNA-based therapeutics use messenger RNA (mRNA) to instruct cells to produce proteins that may treat or prevent diseases. This cutting-edge approach targets conditions at the molecular level, leading to personalized medicine. For instance, in June 2024, ReCode Therapeutics, Inc., a US-based biotechnology company, launched RCT1100, an investigational inhaled mRNA therapy. The therapy received orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating primary ciliary dyskinesia. RCT1100 aims to restore ciliary function by delivering DNAI1 mRNA directly to airway cells, addressing a critical unmet need for the estimated 45,000 individuals affected by PCD in the U.S., as there are currently no disease-modifying treatments or cures for this condition.
In October 2024, PCD Research, a UK-based charitable organization focused on primary ciliary dyskinesia research, partnered with the Nucleic Acid Therapy Accelerator (NATA) to advance therapies for primary ciliary dyskinesia. The collaboration aims to co-fund a grant dedicated to developing innovative treatments for PCD, a rare genetic disorder that impairs respiratory function. The partnership seeks to support groundbreaking research that will improve treatment options and outcomes for individuals affected by this progressive and debilitating condition. NATA is a UK-based research initiative specializing in nucleic acid therapeutics.
Major companies operating in the primary ciliary dyskinesia (pcd) market are Centogene NV, Revvity Inc, Quest Diagnostics Incorporated, Nationwide Children’s Hospital, Children’s Healthcare of Atlanta, National Jewish Health, Guy's and St Thomas' NHS Foundation Trust, University Hospital Southampton, Vanderbilt University Medical Center, Stanford Medicine, Mayo Foundation for Medical Education and Research, UNC School of Medicine, UAB Health System, University Hospital Münster, DNA Labs India Pvt Ltd, Parion Sciences Inc, ReCode Therapeutics Inc, PCD Foundation, PCD Research Consortium, European PCD Network.
North America was the largest region in the primary ciliary dyskinesia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary ciliary dyskinesia (pcd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the primary ciliary dyskinesia (pcd) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the primary ciliary dyskinesia market by increasing the cost of imported diagnostic equipment, therapeutic devices, and specialized medications. Segments such as genetic testing kits and airway clearance therapy devices are particularly impacted, with regions like North America and Europe facing import duty challenges for specialized medical devices. This has led to higher treatment costs and slowed procurement for small clinics. On the positive side, tariffs encourage local manufacturing of diagnostic tools and therapies, driving innovation and domestic production capabilities.
The primary ciliary dyskinesia (pcd) market research report is one of a series of new reports that provides primary ciliary dyskinesia (pcd) market statistics, including primary ciliary dyskinesia (pcd) industry global market size, regional shares, competitors with a primary ciliary dyskinesia (pcd) market share, detailed primary ciliary dyskinesia (pcd) market segments, market trends and opportunities, and any further data you may need to thrive in the primary ciliary dyskinesia (pcd) industry. This primary ciliary dyskinesia (pcd) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Primary ciliary dyskinesia (PCD) is a rare inherited disorder that affects the normal function and structure of cilia, which are microscopic, hair-like structures found in the airways, ears, and reproductive tract. Understanding and diagnosing PCD is essential for managing symptoms early and improving quality of life through targeted therapies.
The main types of treatment for primary ciliary dyskinesia (PCD) include antibiotics, airway clearance therapies, surgical interventions, and other supportive therapies. Antibiotics help treat respiratory bacterial infections, prevent lung damage, and maintain airway health. PCD is diagnosed through various methods, such as genetic testing, imaging techniques, clinical evaluation, and lung function tests. The treatments are distributed through multiple channels, including direct sales, online pharmacies, third-party distributors, and retail pharmacies. End-users of PCD treatments include hospitals, specialty clinics, diagnostic laboratories, and other healthcare providers.
The primary ciliary dyskinesia market consists of revenues earned by entities by providing services such as pulmonary rehabilitation, home healthcare services, and genetic counselling. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary ciliary dyskinesia market includes sales of immunofluorescence microscopy, transmission electron tomography, and whole-exome sequencing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Primary Ciliary Dyskinesia (PCD) Market Characteristics
3. Primary Ciliary Dyskinesia (PCD) Market Supply Chain Analysis
4. Global Primary Ciliary Dyskinesia (PCD) Market Trends and Strategies
5. Primary Ciliary Dyskinesia (PCD) Market Analysis of End Use Industries
7. Global Primary Ciliary Dyskinesia (PCD) Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Primary Ciliary Dyskinesia (PCD) Total Addressable Market (TAM) Analysis for the Market
9. Primary Ciliary Dyskinesia (PCD) Market Segmentation
10. Primary Ciliary Dyskinesia (PCD) Market Regional and Country Analysis
11. Asia-Pacific Primary Ciliary Dyskinesia (PCD) Market
12. China Primary Ciliary Dyskinesia (PCD) Market
13. India Primary Ciliary Dyskinesia (PCD) Market
14. Japan Primary Ciliary Dyskinesia (PCD) Market
15. Australia Primary Ciliary Dyskinesia (PCD) Market
16. Indonesia Primary Ciliary Dyskinesia (PCD) Market
17. South Korea Primary Ciliary Dyskinesia (PCD) Market
18. Taiwan Primary Ciliary Dyskinesia (PCD) Market
19. South East Asia Primary Ciliary Dyskinesia (PCD) Market
20. Western Europe Primary Ciliary Dyskinesia (PCD) Market
21. UK Primary Ciliary Dyskinesia (PCD) Market
22. Germany Primary Ciliary Dyskinesia (PCD) Market
23. France Primary Ciliary Dyskinesia (PCD) Market
24. Italy Primary Ciliary Dyskinesia (PCD) Market
25. Spain Primary Ciliary Dyskinesia (PCD) Market
26. Eastern Europe Primary Ciliary Dyskinesia (PCD) Market
27. Russia Primary Ciliary Dyskinesia (PCD) Market
28. North America Primary Ciliary Dyskinesia (PCD) Market
29. USA Primary Ciliary Dyskinesia (PCD) Market
30. Canada Primary Ciliary Dyskinesia (PCD) Market
31. South America Primary Ciliary Dyskinesia (PCD) Market
32. Brazil Primary Ciliary Dyskinesia (PCD) Market
33. Middle East Primary Ciliary Dyskinesia (PCD) Market
34. Africa Primary Ciliary Dyskinesia (PCD) Market
36. Primary Ciliary Dyskinesia (PCD) Market Competitive Landscape and Company Profiles
37. Primary Ciliary Dyskinesia (PCD) Market Other Major and Innovative Companies
40. Primary Ciliary Dyskinesia (PCD) Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Primary Ciliary Dyskinesia (PCD) Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses primary ciliary dyskinesia (pcd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for primary ciliary dyskinesia (pcd)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The primary ciliary dyskinesia (pcd) market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Treatment: Antibiotics; Airway Clearance Therapies; Surgical Interventions; Other Treatments2) By Method: Genetic Testing; Imaging Techniques; Clinical Evaluation; Lung Function Tests
3) By Distribution Channel: Direct Sales; Online Pharmacies; Third-party Distributors; Retail Pharmacies
4) By End-User: Hospitals; Specialty Clinics; Diagnostic Laboratories; Other End-Users
Subsegments:
1) By Antibiotics: Macrolides; Penicillins; Cephalosporins; Fluoroquinolones; Aminoglycosides2) By Airway Clearance Therapies: Chest Physiotherapy; High-Frequency Chest Wall Oscillation (HFCWO); Positive Expiratory Pressure (PEP) Therapy; Intrapulmonary Percussive Ventilation (IPV); Oscillatory Positive Expiratory Pressure (OPEP)
3) By Surgical Interventions: Sinus Surgery; Tympanostomy Tube Placement; Lung Transplantation
4) By Other Treatments: Mucolytics; Immunomodulatory Therapies; Gene Therapy; Stem Cell Therapy
Companies Mentioned: Centogene NV; Revvity Inc; Quest Diagnostics Incorporated; Nationwide Children’s Hospital; Children’s Healthcare of Atlanta; National Jewish Health; Guy's and St Thomas' NHS Foundation Trust; University Hospital Southampton; Vanderbilt University Medical Center; Stanford Medicine; Mayo Foundation for Medical Education and Research; UNC School of Medicine; UAB Health System; University Hospital Münster; DNA Labs India Pvt Ltd; Parion Sciences Inc; ReCode Therapeutics Inc; PCD Foundation; PCD Research Consortium; European PCD Network
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Primary Ciliary Dyskinesia (PCD) market report include:- Centogene NV
- Revvity Inc
- Quest Diagnostics Incorporated
- Nationwide Children’s Hospital
- Children’s Healthcare of Atlanta
- National Jewish Health
- Guy's and St Thomas' NHS Foundation Trust
- University Hospital Southampton
- Vanderbilt University Medical Center
- Stanford Medicine
- Mayo Foundation for Medical Education and Research
- UNC School of Medicine
- UAB Health System
- University Hospital Münster
- DNA Labs India Pvt Ltd
- Parion Sciences Inc
- ReCode Therapeutics Inc
- PCD Foundation
- PCD Research Consortium
- European PCD Network
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.53 Billion |
| Forecasted Market Value ( USD | $ 0.68 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
